Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 18 of 6351
-
Supercharged immune cells take aim at cancer and viruses in one shot
Cure OngoingSubjects are having a bone marrow or SCT for either a type of cancer of the blood called Leukemia or a cancer of the lymph nodes called non- Hodgkin's Lymphoma. Although a transplant can cure leukemia or lymphoma, some people will relapse. In those who relapse, current treatment …
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Cure
Last updated Jul 16, 2026 00:00 UTC
-
Can sound waves destroy breast tumors without a scalpel?
Cure CompletedNon-randomized, Single Arm Clinical study to Evaluate the Safety and Effectiveness of MR Guided Focused Ultrasound Surgery in the Treatment of Early Breast Carcinomas
Sponsor: InSightec • Aim: Cure
Last updated Sep 10, 2026 00:00 UTC
-
Could a diabetes prevention strategy also fight heart disease and cancer?
Prevention CompletedThe Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT, 2 hour glucose of 140-199 …
Phase 3 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Prevention
Last updated Aug 01, 2026 00:00 UTC
-
Ebola antibody cocktail made available in emergency outbreak
Disease control Expanded accessProvide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Cow-Hemoglobin infusion could save lives when blood is not an option
Disease control Expanded access (ended)HBOC-201 provides an oxygen treatment bridge and can be used to eliminate, delay, or reduce the need for red blood cell transfusions in anemic patients This is an expanded access IND protocol, and will provide treatment with HBOC-201 to severely anemic adults for whom blood is n…
Sponsor: Michael Boisen • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Triple-Attack CAR-T cells take aim at stubborn neuroblastoma
Disease control Not yet recruitingThe purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple 4SCAR-T cell therapy which targets GD2, PSMA and CD276 surface antigens in patients with relapsed and refractory neuroblastoma (NB). Another goal of the study is to understand the fun…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a new drug extend remission in advanced ovarian cancer?
Disease control Not yet recruitingThe purpose of this study is to evaluate INCB123667 in Combination With Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Participants With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Overexpressing Cyclin E1.
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
Can adding capivasertib slow metastatic breast cancer?
Disease control Not yet recruitingThe purpose of this research is to see if adding the investigational targeted drug capivasertib to standard endocrine therapy (hormone-blocking treatment) combined with a medicine that slows cancer cell growth can improve response to treatment for patients with metastatic breast …
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new drug outperform chemotherapy for tough esophageal cancer?
Disease control Not yet recruitingThe study compares the overall survival (OS) of FH-006 and the second-line chemotherapy selected by the investigators for treating esophageal squamous cell carcinoma patients.
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a Pre-Surgery drug combo wipe out early breast cancer?
Disease control Not yet recruitingThe goal of this clinical trial is to compare the effectiveness of several treatment regimens for stage I triple negative breast cancer before surgery. The main question it aims to answer is if these regimens will reduce or completely remove all cancer cells before surgery.
Phase 2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a Four-Drug combo tame Ultra-High-Risk myeloma?
Disease control Not yet recruitingThis is a prospective, single-arm, single-center interventional study designed to evaluate the safety and efficacy of Elra-Isa-VR in patients with newly diagnosed ultra-high-risk multiple myeloma.
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
One shot, six protections: can a new vaccine match current standards?
Vaccine Not yet recruitingThis study is a phase 3, randomized, observer-blinded, active-controlled, multicenter study to evaluate the immunogenicity and safety of BK1803 in healthy infants aged 2 months to less than 7 months. Participants will be randomized to receive either BK1803 or a control regimen c…
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Vaccine
Last updated Aug 30, 2026 00:00 UTC
-
Can a targeted drug duo hold off ovarian cancer's return?
Disease control Not yet recruitingThe primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as measured by progression-free survival (PFS) as assessed b…
Phase 3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Personalized vaccine aims to stop lynch syndrome cancers before they start
Prevention Not yet recruitingThe primary objective is to assess the effect of vaccination with neopeptide-loaded dendritic cells on disease-free survival (DFS) compared to placebo in LS subjects who are known to be carrier of a germline MMR-gene mutation with no signs of disease.
Phase 3 • Sponsor: Radboud University Medical Center • Aim: Prevention
Last updated Jun 27, 2026 12:37 UTC
-
Can a Dual-Chamber heart pump save the failing heart?
Disease control Not yet recruitingThe objective of this clinical investigation is to evaluate the safety and efficacy of the DuoCor 2 Ventricular Assist System (DuoCor 2 VAS) in subjects with advanced biventricular heart failure requiring circulatory support. Each subject receiving the DuoCor 2 VAS will be evalu…
Sponsor: Shenzhen Core Medical Technology CO.,LTD. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a drug combo outsmart a tough breast cancer subtype?
Disease control Not yet recruitingThis study is a prospective, open-label, phase III, randomized controlled clinical trial. It is planned to screen patients with inoperable locally advanced or metastatic triple-negative breast cancer of the LAR subtype. A total of 180 patients are planned to be enrolled.
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart a tough blood cancer?
Disease control Not yet recruitingThis study aims to compare the efficacy and safety of ICP-248 in combination with orelabrutinib versus pirtobrutinib in patients with relapsed or refractory mantle cell lymphoma (r/r MCL).
Phase 3 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a Triple-Drug combo outsmart pancreatic cancer?
Disease control Not yet recruitingThe goal of this clinical trial is to evaluate the safety and efficacy of GnP combined with SHR-1701 and Apatinib as first-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Phase 1/2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a Late-Acting clot buster improve stroke recovery?
Disease control Not yet recruitingThe HOPE-MeVO study aims to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in patients with acute ischemic stroke due to medium vessel occlusion presenting 4.5 to 24 hours after stroke onset or last known well. Eligible patients will be …
Phase 3 • Sponsor: The First Affiliated Hospital of Anhui Medical University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can mRNA technology outsmart the flu in older adults?
Vaccine Not yet recruitingThis study will compare an investigational mRNA flu vaccine with a licensed flu vaccine in adults 65 years of age and older. Participants will receive one injection and will be followed during the flu season. The study will measure prevention of laboratory-confirmed flu illness, …
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Sep 06, 2026 00:00 UTC